The highest levels of FOXP3+ Tregs (3.5 ± 0.5%), > 15 fold increase compared with HFDs, were documented in patients whose tumours failed to undergo or had a poor pathological response (grades 1 and 2, respectively) to 8 cycles of NAC (spearmans Rho p = 0.004) (Figure 1A). This evidence concerns the gene FOXP3 and neoplasm.